Australia markets closed

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.61-0.21 (-0.68%)
At close: 04:00PM EDT
31.21 +0.60 (+1.96%)
After hours: 05:12PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.42B
Enterprise value 1.68B
Trailing P/E 20.27
Forward P/E 11.44
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.40
Price/book (mrq)1.60
Enterprise value/revenue 2.47
Enterprise value/EBITDA 8.96

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-26.28%
S&P500 52-week change 328.04%
52-week high 342.63
52-week low 325.33
50-day moving average 328.37
200-day moving average 330.68

Share statistics

Avg vol (3-month) 3646.53k
Avg vol (10-day) 31.57M
Shares outstanding 546.55M
Implied shares outstanding 646.55M
Float 846.07M
% held by insiders 11.26%
% held by institutions 1109.73%
Shares short (30 Apr 2024) 43.6M
Short ratio (30 Apr 2024) 48.31
Short % of float (30 Apr 2024) 411.24%
Short % of shares outstanding (30 Apr 2024) 47.74%
Shares short (prior month 28 Mar 2024) 43.74M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 10.34%
Operating margin (ttm)9.05%

Management effectiveness

Return on assets (ttm)3.76%
Return on equity (ttm)8.49%

Income statement

Revenue (ttm)681.75M
Revenue per share (ttm)14.71
Quarterly revenue growth (yoy)4.20%
Gross profit (ttm)N/A
EBITDA 167.82M
Net income avi to common (ttm)70.47M
Diluted EPS (ttm)1.51
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)325.89M
Total cash per share (mrq)7
Total debt (mrq)581.78M
Total debt/equity (mrq)65.21%
Current ratio (mrq)5.81
Book value per share (mrq)19.18

Cash flow statement

Operating cash flow (ttm)184.62M
Levered free cash flow (ttm)146.28M